Iteos Net Income From Continuing Ops from 2010 to 2024

ITOS Stock  USD 8.19  0.05  0.61%   
Iteos Therapeutics Net Loss yearly trend continues to be comparatively stable with very little volatility. Net Loss is likely to outpace its year average in 2024. From the period from 2010 to 2024, Iteos Therapeutics Net Loss quarterly data regression had mean square error of 4967.4 T and mean deviation of  42,058,997. View All Fundamentals
 
Net Loss  
First Reported
2019-06-30
Previous Quarter
-38.2 M
Current Value
-7.1 M
Quarterly Volatility
51 M
 
Covid
Check Iteos Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Iteos Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 3.4 M, Net Interest Income of 32.4 M or Interest Income of 32.4 M, as well as many indicators such as Price To Sales Ratio of 32.65, Dividend Yield of 0.0 or PTB Ratio of 0.65. Iteos financial statements analysis is a perfect complement when working with Iteos Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Iteos Therapeutics Correlation against competitors.
For more information on how to buy Iteos Stock please use our How to Invest in Iteos Therapeutics guide.

Latest Iteos Therapeutics' Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Iteos Therapeutics over the last few years. It is Iteos Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Iteos Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Pretty Stable
   Net Income From Continuing Ops   
       Timeline  

Iteos Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(2,134,740)
Coefficient Of Variation(3,250)
Mean Deviation42,058,997
Median(18,057,000)
Standard Deviation69,388,019
Sample Variance4814.7T
Range276.2M
R-Value0.20
Mean Square Error4967.4T
R-Squared0.04
Significance0.46
Slope3,179,126
Total Sum of Squares67405.8T

Iteos Net Income From Continuing Ops History

2024-58.6 M
2023-61.6 M
202296.7 M
2021214.5 M
2020-38 M
2019-22.5 M

About Iteos Therapeutics Financial Statements

Iteos Therapeutics shareholders use historical fundamental indicators, such as Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Iteos Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Iteos Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Iteos Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss-61.6 M-58.6 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Iteos Stock Analysis

When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.